European equities traded in the US as American depositary receipts edged lower late Wednesday morning, declining 0.1% to 1,530.89 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and semiconductor company Sequans Communications (SQNS), which rose 6.1% and 6% respectively. They were followed by biotech firm Evaxion (EVAX) and financial services company ING (ING), which were up 5.6% and 2.9% respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biopharmaceutical company Genfit (GNFT), which dropped 16% and 4.8% respectively. They were followed by software firm SAP (SAP) and biotech firm BioNTech (BNTX), which fell 3.1% and 1.4% respectively.

From the UK and Ireland, the gainers were led by biotech company Trinity Biotech (TRIB) and insurance provider Prudential (PUK), which advanced 4.5% and 3.4% respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which increased 1% and 0.6% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma (MREO), which lost 7.3% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and telecommunications operator Vodafone (VOD), which were down 1.4% and 1.2% respectively.